The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 344:520-522 February 15, 2001 Number 7
NextNext

Should Patients with Drug-Resistant HIV-1 Continue to Receive Antiretroviral Therapy?

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Deeks, S. G.
-PubMed Citation
The ultimate goal of antiretroviral therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection is to cure the infection. Failing that, the objective is to stop the progression of the disease and allow the immune system some degree of recovery. Failing that, therapy is used to slow the disease process and buy patients time, during which new and better therapies may be discovered.

The strong correlation between the amount of HIV-1 circulating in the blood and the rate at which AIDS develops1 has allowed measurements of viral RNA in the blood plasma to be used as a ready . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.